Drug interactions of Elacestrant

1 Effect of Other Drugs on Elacestrant

Strong and Moderate CYP3A4 Inhibitors

Avoid concomitant use of strong or moderate CYP3A inhibitors with Elacestrant. 

Elacestrant is a CYP3A4 substrate. Concomitant use of a strong or moderate CYP3A4 inhibitor increase  elacestrant exposure, which may increase the risk of adverse  reactions of Elacestrant.

Strong and Moderate CYP3A4 Inducers

Avoid concomitant use of strong or moderate CYP3A inducers with Elacestrant.

Elacestrant is a CYP3A4 substrate. Concomitant use of a strong or moderate CYP3A4 inducer decreases  elacestrant exposure, which may decrease effectiveness of Elacestrant.

2 Effect of Elacestrant on Other Drugs

P-gp Substrates

Reduce the dosage of P-gp substrates per their Prescribing Information when minimal concentration changes may lead to serious or life-threatening adverse reactions.

Elacestrant is a P-gp inhibitor. Concomitant use of Elacestrant with a P-gp substrate increased the concentrations of P-gp substrate. which may increase the adverse  reactions associated with a P-gp substrate.

BCRP Substrates

Reduce the dosage of BCRP substrates per their Prescribing Information when minimal concentration changes may lead to serious or life-threatening adverse reactions.

Elacestrant is a BCRP inhibitor. Concomitant use of Elacestrant with a BCRP substrate increased the  plasma concentrations of BCRP substrate, which may increase the  adverse reactions associated with a BCRP substrate.

from FDA，2023.05